Effects of Antidepressant Drugs on Electroencephalography Alpha Power: Importance of Study Duration

Biological Psychiatry

Volumn 64, Issue 10, 2008, Pages

  Wiśniewski, Grzegorz S ^a   McAllister Williams, R Hamish ^b   Jakitowicz, Janusz ^c   Nowicki, Zbigniew ^c   Majkowicz, Mikołaj ^c   Trzebiatowska, Iwona A ^c  

^a TYNE AND WEAR NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; FLUOXETINE; FLUVOXAMINE; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; PIRLINDOLE;

BRAIN REGION; CLINICAL TRIAL; DEPRESSION; DRUG EFFECT; ELECTROENCEPHALOGRAPHY; HAMILTON SCALE; HUMAN; LETTER; PRIORITY JOURNAL; TREATMENT RESPONSE;

ALPHA RHYTHM; ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSIVE DISORDER; HUMANS;

EID: 54149092909     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2008.05.036     Document Type: Letter

References (16)

1. Bruder G.E., Sedoruk J.P., Stewart J.W., McGrath P.J., Quitkin F.M., and Tenke C.E. Electroencephalographic alpha measures predict therapeutic response to a selective serotonin reuptake inhibitor antidepressant: Pre- and post-treatment findings. Biol Psychiatry 63 (2008) 1171-1177
2. Saletu B., Anderer P., Saletu-Zyhlartz G.M., Arnold O., and Pascual-Marqui R.D. Classification and evaluation of the pharmacodynamics of psychotropic drugs by single-lead pharmaco-EEG, EEG mapping and tomography (LORETA). Methods Find Exp Clin 24 (2002) 97-120
3. Ulrich G., Haug H.J., Stieglitz R.D., and Fahndrich E. Are there distinct biochemical subtypes of depression?. EEG characteristics of clinically defined on-drug responders and non-responders. J Affect Disord 15 (1988) 181-185
4. Knott V.J., Telner J.I., Lapierre Y.D., Browne M., and Horn E.R. Quantitive EEG in the prediction of antidepressant response to imipramine. J Affect Disord 39 (1996) 175-184
5. Galdiresi S., Mucci A., Bucci P., Mignone M.L., and Maj M. Influence of moclobemide on cognitive functions of nine depressed patients: A pilot trial. Neuropsychobiology 33 (1996) 48-54
6. Siepmann M., Krause S., Joraschky P., Muck-Weymann M., and Kirch W. The effects of St John's wort extract on heart rate variability, cognitive function and quantitative EEG: A comparison with amitryptyline and placebo in healthy men. Br J Clin Pharmacol 54 (2002) 277-282
7. Tarn M., Edwards J.G., and Sedgwick E.M. Fluoxetine, amitryptyline and electroencephalogram. J Affect Disord 29 (1993) 7-10
8. Kwon J.S., Youn T., and Jung H.Y. Right hemisphere abnormalities in major depression: Quantitative EEG findings before and after treatment. J Affect Disord 40 (1996) 169-173
9. Wisniewski G, Majkowicz M, Nowicki Z, Jakitowicz J, Trzebiatowska I, Iwan B (2006): Changes in EEG Alfa spectral power as a possible predictor of a clinical response in 6-week pharmacotherapy of depression. In: Kinoshita T, editor. Program and abstracts of the 14th Biennial Congress of International Pharmaco-EEG (IPEG) Society; September 7-10, 2006; Hyogo Prefecture, Japan, 59.
10. Ulrich G., Renfordt E., Zeller G., and Frick K. Interrelation between changes in the EEG and psychopathology under pharmacotherapy for endogenous depression. A contribution to the predictor question. Pharmacopsychiatry 17 (1984) 178-183
11. Hermann W.M., and Winterer G. The concept of vigilance and aspects of thymoleptic effects on depressive disorder. Eur Neuropsychopharmacol 6 (1996) 210
12. Saletu B., and Grunberger J. On acute and chronic CNS effects of antidepressants in normals: Neurophysiological, behavioural and pharmacokinetic studies with pirlindol. Methods Find Exp Clin 7 (1985) 137-151
13. Cook I.A., Leuchter A.F., Witte E.A., Morgan M., and Abrams M. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry 159 (2002) 122-129
14. Pizzagalli D.A., Oakes T.R., Fox A.S., Chung M.K., Larson C.L., Abercrombie H.C., et al. Functional but not structural subgenual prefrontal cortex (PFC) abnormalities in melancholia. Mol Psychiatr 9 (2004) 393-405
15. Hansen E.S., Prichep L.S., Bolwig T.G., and John E.R. Quantitative electroencephalography in OCD patients treated with paroxetine. Clin EEG Neurosci 34 (2003) 70-75
16. Saletu B., and Grunberger J. Classification and determination of cerebral bioavailability of fluoxetine: Pharmacokinetic, pharmaco-EEG, and psychometric analyses. J Clin Psychiatry 46 (1985) 45-52